Remifentanil and ciprofol

PreclinicalSmall molecule

Remifentanil and ciprofol is one of 4 small molecule programs targeting Postoperative Recovery. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Postoperative RecoveryActive, not recruiting

Postoperative RecoveryPreclinical

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Postoperative Recovery

#DrugCompanyPhaseTrials

Dalgan

AstraZeneca

Approved

1 2

Platelet-Rich Fibrin (PRF)

FFederal University of São Paulo

Preclinical

1 3

Remifentanil and ciprofol

NNorthern Jiangsu People's Hospital

Preclinical

1 4

Moderate Intensity Statin

YYonsei University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Postoperative Recovery1 trial

The Impact of Low-Dose Esketamine Combined With Ciprofol on the Quality of Early Postoperative Recovery Among Elderly Patients Undergoing Painless Gastroscopy

Active, not recruiting·NNorthern Jiangsu People's Hospital·N/A·NCT06617039·376 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Remifentanil and ciprofol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Remifentanil and ciprofol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Remifentanil and ciprofol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Northern Jiangsu People's Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: NNorthern Jiangsu People's Hospital

Remifentanil and ciprofol

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Postoperative Recovery1 trial

References

Drug Info

Quick Facts

Related News